

Leading Product Across all Therapeutic Areas

TABLE OF CONTENT

Chapter 1
Executive Summary

Executive Summary

- This report consists of deep comparative analysis of various therapeutic areas and their related products
- The objective here, was to select best therapeutic area based on certain parameters and applying another matrix to identify top innovative and generic drugs in each Therapeutic area
- Oncology come out as the best and most promising therapeutic area with immense potential
- Comparison between all innovative and generic drugs in oncology was also made & top 10 products were selected, Further more deep analysis were done on these top 10 product.
- This overall report will help you in understanding opportunities lies in Oncology and their products

Research Methodology

Step 1

Therapeutic area list were prepared

Step 2

On the basis of various parameters* best therapeutic area was selected

Step 3

Marketed Products under selected therapeutic area were listed

Step 4

Matrix was developed separately for products & analyzed

Result

Lucrative Products were selected to cover the detailed info for further decision making

* For various parameters selected kindly refer to slide No. 8

Chapter 2
Therapeutic Area Selection

Therapeutic Area Catalogue

Cardiology	Nephrology	Dermatology	Endocrinology
Genetic Disease	Infections and Infectious Disease	Hepatology	Gastroenterology
Hematology	Immunology	Musculoskeletal	Neurology
Nutrition and Weight Loss	Gynecology	Oncology	Ophthalmology
Orthopedics	Otolaryngology	Neonatology	Respiratory Disease
Urology	Dental and Oral Health		

Parameters for Therapeutic Area Selection



Oncology Came out to be Promising Therapeutic Area

http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/incidence#heading-Zero

Chapter 3
Oncology Overview

Introduction

Cancer begins when cells in a part of the body start to grow out of control. There are many kinds of cancer, but they all start because of out-of-control growth of abnormal cells

Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012 .



Indication Wise Market Segmentation



Geographical Area Wise Cancer Incidence , Mortality & Prevalence (2012)

Estimated numbers (thousands)	Men			Women			Both sexes		
	Incidence	Mortality	5-year prev.	Incidence	Mortality	5-year prev.	incidence	Mortality	5-year prev.
World	7410	4653	15296	6658	3548	17159	14068	8202	32455
More developed regions	3227	1592	8550	2827	1287	8274	6054	2878	16823
Less developed regions	4184	3062	6747	3831	2261	8885	8014	5323	15632
WHO Africa region (AFRO)	265	205	468	381	250	895	645	456	1363
WHO Americas region (PAHO)	1454	677	3843	1429	618	4115	2882	1295	7958
WHO East Mediterranean region (EMRO)	263	191	461	293	176	733	555	367	1194
WHO Europe region (EURO)	1970	1081	4791	1744	852	4910	3715	1933	9701
WHO South-East Asia region (SEARO)	816	616	1237	908	555	2041	1724	1171	3278
WHO Western Pacific region (WPRO)	2642	1882	4493	1902	1096	4464	4543	2978	8956
European Union (EU-28)	1430	716	3693	1206	561	3464	2635	1276	7157
United States of America	825	324	2402	779	293	2373	1604	617	4775
China	1823	1429	2496	1243	776	2549	3065	2206	5045
India	477	357	665	537	326	1126	1015	683	1790

es/fact_sheets_cancer.aspx

Chapter 4
No of Molecules in Oncology

Number of Molecules



Type of Molecules



*25 Drugs administered by oral route and 54 are parenteral formulations

*27 Drugs administered by oral route and 29 are parenteral formulations

Worldwide No. of Under Development Products

Development Phase	No. of Molecules
Preclinical	150
Phase I & Phase II	157
Phase III	57
Total	364





Chapter 5
Criteria Consider for Comparison

Criteria



Chapter 6
Analysis and Top 10 Products

Top Ten Products in Each Category



Chapter 7
Deep Analysis for Top 10 Products in Each Category

Generic

Capecitabine

General Details

Innovator- Hoffmann La Roche (Roche)

Developer- Chugai (Roche)

Total Manufacturers – 60 Worldwide

Total Buyer 62 Worldwide

Patent Expired in 2007

Financial

Sales (Kg)





Technical-Mechanism of Action and Indication



Innovative

Pemetrexed

Basic Information

Innovator
Princeton University

Developer
Eli Lilly

Patent Expiry
2022 (vitamin dosage regimen patent plus pediatric exclusivity).

Technical Information

Indication
Non-Squamous Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma

MOA
Multitargeted Antifolate That Inhibits Enzymes Involved In Folate Metabolism And Purine And Pyrimidine Synthesis.

Adverse drug reaction
Fatigue, Nausea, and Anorexia

Growth Rate of Product- 3%

Sale (Mn $)



Clinical Trial	Efficacy	Safety
Drug (Pemetrexed+Cisplatin)	Median overall survival- 10.3	The most common adverse reactions were fatigue, nausea, and anorexia
Phase III	Median progress ion-free survival- 4.8	Additional common adverse reactions during therapy with ALIMTA vomiting, neutropenia, leukopenia, anemia, pharyngitis, thrombocytopenia
No of Patients 862	Overall response rate- 27.1%	
Patient Segmentation	Non-Small Cell Lung Cancer patients	
Dosage and dosing	Dose of 500 mg/m2 with cisplatin administered intravenously at a dose of 75 mg/m2	
Trial design	Multi-Center, Randomized, Open-Label	

Chapter 8
SWOT Analysis

SWOT Analysis

-STRENGTH

To be Subscribed

WEAKNESS

-To be Subscribed

OPPORTUNITIES

-To be Subscribed

THREAT

-To be Subscribed

Contact us!

For market research report of any product contact us :-
Life science Intellipedia Pvt Ltd
Suite no- 101, C- 104, Sector- 65 Noida, UP- 201301
Contact No- 0120 6900 550-565
Email address- sales@lifescienceintellipedia.com